Generic name: upadacitinib 15mg
Dosage form: tablet, extended release
Medically reviewed by Drugs.com. Last updated on Jul 14, 2020.
Dosage in Rheumatoid Arthritis
The recommended oral dose of RINVOQ is 15 mg once daily with or without food [see Clinical Pharmacology (12.3)].
Important Administration Instructions
- RINVOQ initiation is not recommended in patients with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1000 cells/mm3, or hemoglobin level less than 8 g/dL [see Warnings and Precautions (5.5)].
- RINVOQ is not recommended for use in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].
- RINVOQ tablets should be swallowed whole. RINVOQ should not be split, crushed, or chewed.
RINVOQ treatment should be interrupted if a patient develops a serious infection until the infection is controlled [see Warnings and Precautions (5.1)].
|Absolute Neutrophil Count (ANC)||Treatment should be interrupted if ANC is less than 1000 cells/mm3 and may be restarted once ANC return above this value|
|Absolute Lymphocyte Count (ALC)||Treatment should be interrupted if ALC is less than 500 cells/mm3 and may be restarted once ALC return above this value|
|Hemoglobin (Hb)||Treatment should be interrupted if Hb is less than 8 g/dL and may be restarted once Hb return above this value|
|Hepatic transaminases||Treatment should be interrupted if drug-induced liver injury is suspected|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Frequently Asked Questions
More about Rinvoq (upadacitinib)
- Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 23 Reviews
- Drug class: antirheumatics
- FDA Approval History